MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 11, Issue 6, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-09
DOI
10.1038/s41419-020-2646-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma
- (2020) Stephen B. Keysar et al. CANCER RESEARCH
- BH3 mimetics: Weapons of cancer cell destruction
- (2019) Tríona Ní Chonghaile Science Translational Medicine
- BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
- (2019) Benoît Tessoulin et al. Frontiers in Oncology
- Recent advances in the development of Mcl-1 inhibitors for cancer therapy
- (2019) Alexander W. Hird et al. PHARMACOLOGY & THERAPEUTICS
- Current approaches in identification and isolation of cancer stem cells
- (2019) Maryam Akbarzadeh et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
- (2019) Dana Prukova et al. CLINICAL CANCER RESEARCH
- BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
- (2019) Erinna F. Lee et al. Cell Death & Disease
- Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
- (2019) Joan Montero et al. Nature Communications
- Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
- (2019) Matthew J. Sale et al. Nature Communications
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
- (2018) Zhaodong Li et al. LEUKEMIA
- Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition
- (2018) Clare E. Weeden et al. ONCOGENE
- Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol
- (2018) Monica Marzagalli et al. Scientific Reports
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
- (2018) Donia M. Moujalled et al. LEUKEMIA
- BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
- (2018) Nabanita Mukherjee et al. Cell Death & Disease
- Sphere-Formation Assay: Three-Dimensional in vitro Culturing of Prostate Cancer Stem/Progenitor Sphere-Forming Cells
- (2018) Hisham F. Bahmad et al. Frontiers in Oncology
- Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy
- (2018) Ryuji Yamaguchi et al. PHARMACOLOGY & THERAPEUTICS
- Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling
- (2017) Simon J. Cook et al. FEBS Journal
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Down-Regulation of SOX2 Underlies the Inhibitory Effects of the Triphenylmethane Gentian Violet on Melanoma Cell Self-Renewal and Survival
- (2016) Silvia Pietrobono et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Combining a GSI and BCL-2 inhibitor to overcome melanoma’s resistance to current treatments
- (2016) Nabanita Mukherjee et al. Oncotarget
- Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells
- (2016) Nabanita Mukherjee et al. Oncotarget
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells
- (2015) Nabanita Mukherjee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells
- (2015) Nabanita Mukherjee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment
- (2015) Mariusz L. Hartman et al. PLoS One
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
- (2015) Neel M. Fofaria et al. Oncotarget
- Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs
- (2015) Che-Hsin Lee et al. Oncotarget
- SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells
- (2014) R Santini et al. ONCOGENE
- Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy
- (2014) Nethia Mohana-Kumaran et al. Pigment Cell & Melanoma Research
- Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics
- (2014) Dennie T. Frederick et al. PLoS One
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
- (2012) D. Wroblewski et al. CARCINOGENESIS
- HEDGEHOG-GLI Signaling Drives Self-Renewal and Tumorigenicity of Human Melanoma-Initiating Cells
- (2012) Roberta Santini et al. STEM CELLS
- Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
- (2011) K. M. Lucas et al. CLINICAL CANCER RESEARCH
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53
- (2011) Steven N. Reuland et al. PLoS One
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
- (2008) A. R. Shoemaker et al. CLINICAL CANCER RESEARCH
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
- (2008) Mark S. Cragg et al. JOURNAL OF CLINICAL INVESTIGATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now